We are live on ! Find out more
ZVSA

ZyVersa Therapeutics
ZVSA

Delisted

ZVSA was delisted on the 16th of July, 2025.

Back to rankings

5 hedge funds and large institutions have $273K invested in ZyVersa Therapeutics in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

150% more funds holding

Funds holding: 2 → 5 (+3)

121% more capital invested

Capital invested by funds: $124K → $273K (+$150K)

0% more ownership

Funds ownership: 0% → 0% (+0%)

Holders
5
Holders Change
+3
Holders Change %
+150%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$83.8K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$35.9K
3
WAG
Winthrop Advisory Group
Massachusetts
+$28.4K
4
TRCT
Tower Research Capital (TRC)
New York
+$9.72K
5
UBS Group
UBS Group
Switzerland
+$6.73K

Top Sellers

Rank Fund Capital Flow
1
CL
CSS LLC
Illinois
-$23K

ZVSA Hedge Fund Activity: Q1 2023 in Review

5 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in ZyVersa Therapeutics (ZVSA) for Q1 2023, worth a combined $273K — up 121% from $124K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new ZVSA positions and 1 closed out — a net gain of 3 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $83.8K. The largest seller was CSS LLC, exiting entirely with an estimated $23K sold.

  • 5 institutional investors held ZyVersa Therapeutics (ZVSA) as of Q1 2023, up from 2 in Q4 2022.
  • Funds reported $273K of ZyVersa Therapeutics stock for Q1 2023, up 121% quarter-over-quarter.
  • 4 funds opened new ZyVersa Therapeutics positions in Q1 2023 and 1 closed out, a net change of +3 holders.
  • The largest ZyVersa Therapeutics buyer in Q1 2023 was Goldman Sachs, an estimated $83.8K added.
  • The largest ZyVersa Therapeutics seller in Q1 2023 was CSS LLC, an estimated $23K sold.

Based on aggregated 13F filings for Q1 2023.